MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

PTC Therapeutics Inc

Închisă

SectorSănătate

48.23 3.63

Rezumat

Modificarea prețului

24h

Curent

Minim

45.44

Maxim

48.7

Indicatori cheie

By Trading Economics

Venit

41M

-66M

Vânzări

16M

213M

EPS

-0.342

Marjă de profit

-30.907

Angajați

939

EBITDA

3M

-47M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+42.92% upside

Dividende

By Dow Jones

Următoarele câștiguri

24 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

765M

4.3B

Deschiderea anterioară

44.6

Închiderea anterioară

48.23

Sentimentul știrilor

By Acuity

31%

69%

96 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

PTC Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 dec. 2024, 12:47 UTC

Principalele dinamici ale pieței

PTC Therapeutics Shares Jump on Pact With Novartis

Comparație

Modificare preț

PTC Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

42.92% sus

Prognoză pe 12 luni

Medie 66.6 USD  42.92%

Maxim 113 USD

Minim 50 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPTC Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

12 ratings

6

Cumpărare

5

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

45.4 / 56.23Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

96 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.